Apogee reiterated its intent to present 52-week maintenance results for Zumi this month, randomizing all patients into quarterly and six-month regimens. The analysis will benchmark approximately 72% EASI-75 and 53% IGA 0/1 maintenance rates against established biologics, providing a fuller picture of long-term durability.

Management plans to initiate two Phase III replicate placebo-controlled trials by year-end, with a third trial including topical corticosteroids to support label indications. The company is funded into the second half of 2028 and targets a 2029 launch for Zumi, aiming to reduce treatment burden with infrequent dosing.

Part B data are expected in Q2 to evaluate a higher-dose maintenance regimen, leveraging exposure-response insights from Part A and external IL-13 studies. The study will assess whether increased exposure can deliver incremental efficacy gains beyond the mid-dose regimen, with roughly five percentage points viewed as clinically meaningful.

Safety observations focus on transient conjunctivitis events lasting under 30 days, with no head and neck erythema or eosinophilia reported. Apogee also highlighted its next-generation pipeline, including head-to-head data for OX40 ligand blocker APG279 versus Dupixent and designs for asthma and eosinophilic esophagitis studies later this year.